throbber
WORLD INTELLECTUAL PROPERTY ORGANIZATION
`Intematlonal Bureau
`
`
`
`INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)
`
`(51) Intemamnal Patent Classiflcafio" 6 1
`
`W0 98/47535 A61K 47/36, 9/00
`
`(11) International Publication Number:
`_
`_
`(43) International Publication Date:
`
`A1
`
`29 October 1998 (29.l0.98)
`
`(21) International Application Number:
`_
`(22) International Filing Date:
`
`PCT/GB98/01147
`
`20 April 1998 (20.04.98)
`
`(81) Designated States: AU, CA, GB, JP, NO, NZ, US, European
`patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR,
`IE, IT, LU, MC, NL, PT, SE).
`
`Published
`With international search report.
`Before the expiration of the time limit for amending the
`claims and to be republished in the event of the receipt of
`amendments.
`
`(30) Priority Data:
`9707934.7
`
`18 April 1997 ( 18.04.97)
`
`GB
`
`(71) Applicant (for all designated States except US): DANBIOSYST
`UK LIMITED [GB/GB]; Albert Einstein Centre, Highfields
`Science Park, Nottingham NG7 2TN (GB).
`
`(72) Inventors; and
`(75) Inventors/Applicants (for US only): WATTS, Peter, James
`[GB/GB]; Flat 2, 47 Highfield Road, West Bridgford,
`Nottingham NG2 6DR (GB). ILLUM, Lisbeth [DK/GB];
`The Park, 19 Cavendish Crescent North, Nottingham NG7
`1BA (GB).
`
`(74) Agent: BASSETI‘, Richard; Eric Potter Clarkson, Park View
`House, 58 The Ropewalk, Nottingham NG1 5DD (GB).
`
`(54) Title:
`
`IMPROVED DELIVERY OF DRUGS TO MUCOSAL SURFACES
`
`125
`
`—U"'—'
`
`Fexofenadine HCIIHP-B-CD
`
`~*~0-~~-'
`
`Fexofenadine HCIIHP-B-CDIpeclin 100
`
`III¢9
`
`~l(II
`
`U!G
`
`(%) 3
`ThereleaseoffexofenadineHCI
`
`
`0
`
`250
`
`500
`
`750
`
`1000
`
`1250
`
`1500
`
`1750
`
`2000
`
`(57) Abstract
`
`Time (Seconds)
`
`Liquid pharmaceutical compositions for administration to a mucosal surface, comprising a therapeutic agent and a pectin with a low
`degree of esterification are described. Such compositions gel, or can be adapted to gel, at the site of application in the absence of an
`extraneous source of divalent metal ions.
`
`   
`

`
`Lannett Holdings, Inc. LAN 1010
`
`
`
`

`
`FOR THE PURPOSES OF INFORMATION ONLY
`
`Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.
`LS
`SI
`Slovenia
`Lesotho
`Slovakia
`SK
`LT
`Lithuania
`SN
`Luxembourg
`Senegal
`Swaziland
`SZ
`Latvia
`TD
`Monaco
`Chad
`TG
`Togo
`Republic of Moldova
`TJ
`Madagascar
`Tajikistan
`TM
`Turkmenistan
`The former Yugoslav
`TR
`Turkey
`Republic of Macedonia
`TT
`Mali
`Trinidad and Tobago
`UA
`Ukraine
`Mongolia
`UG
`Mauritania
`Uganda
`US
`United States of America
`Malawi
`Mexico
`UZ
`Uzbekistan
`VN
`Viet Nam
`Niger
`Netherlands
`YU
`Yugoslavia
`ZW
`Zimbabwe
`Norway
`New Zealand
`Poland
`Portugal
`Romania
`Russian Federation
`Sudan
`Sweden
`Singapore
`
`Albania
`Armenia
`Austria
`Australia
`Azerbaijan
`Bosnia and Herzegovina
`Barbados
`Belgium
`Burkina Faso
`Bulgaria
`Benin
`Brazil
`Belarus
`Canada
`Central African Republic
`Congo
`Switzerland
`Cote d’Ivoire
`Cameroon
`China
`Cuba
`Czech Republic
`Germany
`Denmark
`Estonia
`
`LV
`MC
`MD
`MG
`MK
`
`ML
`MN
`MR
`MW
`MX
`NE
`NL
`NO
`NZ
`PL
`PT
`RO
`RU
`SD
`SE
`SG
`
`ES
`FI
`FR
`GA
`GB
`GE
`GH
`GN
`GR
`HU
`IE
`IL
`IS
`IT
`JP
`KE
`KG
`KP
`
`KR
`KZ
`LC
`LI
`LK
`LR
`
`Spain
`Finland
`France
`Gabon
`United Kingdom
`Georgia
`Ghana
`Guinea
`Greece
`Hungary
`Ireland
`Israel
`Iceland
`Italy
`Japan
`Kenya
`Kyrgyzstan
`Democratic People’s
`Republic of Korea
`Republic of Korea
`Kazakstan
`Saint Lucia
`Liechtenstein
`Sri Lauka
`Liberia
`
`
`
`

`
`WO 98/47535
`
`PCT/GB98/01147
`
`IMPROVED DELIVERY OF DRUGS TO MUCOSAL SURFACES
`
`This invention relates to an improved system for the delivery of drugs to
`
`mucosal surfaces such as the nose, the eye, the vagina, the rectum and the
`
`back of the throat.
`
`10
`
`15
`
`20
`
`25
`
`Administration of therapeutic agents to mucosa is well known in the art.
`
`A variety of drugs may be administered to the nose,
`
`including those
`
`intended for the local
`
`treatment of nasal diseases, nasal vaccines, and
`
`those intended for systemic circulation. Because the nose has a reasonable
`
`surface area and a good blood supply, certain lipophilic drugs, such as
`
`nicotine and propranolol, can be absorbed rapidly into the blood, resulting
`
`in a bioavailability which is similar to that seen with intravenous injection.
`
`More polar drugs are less well absorbed,
`
`though absorption may be
`
`improved by the use of enhancing agents such as surfactants, powders
`
`such as microcrystalline cellulose, gelling microspheres (eg. starch). and
`
`the bioadhesive polymer, chitosan. Examples of these systems are well
`
`known in the art and have been reviewed by Illum and Fisher
`
`in
`
`“Inhalation Delivery of Therapeutic Peptides and Proteins”, Adjei and
`
`Gupta (eds.) Marcel Dekker Inc., New York (1997) 135-184.
`
`In a similar fashion,
`
`it
`
`is useful
`
`to deliver therapeutic agents, such as
`
`drugs and vaccines, to the vaginal cavity for a systemic effect or for the
`
`local
`
`treatment of diseases
`
`(particularly infectious diseases
`
`such as
`
`candidiasis and bacterial vaginitis) as well as for prophylaxis of diseases
`
`(e.g. HIV).
`
`Locally acting formulations may also be used to deliver
`
`contraceptive and spermicidal agents.
`
`
`
`

`
`
`
`‘W0 98/47535
`
`PCT/GB98/01 147
`
`Drugs may also be administered to mucosa in the eye and the rectum in
`
`order to achieve local effects or for systemic activity.
`
`Considerable advantages in terms of improved efficacy are expected to be
`
`gained if a nasally administered formulation were capable of retaining a
`
`drug, a vaccine, or DNA intended for local effect,
`
`in the nose for
`
`relatively long time periods. Previous workers have used a variety of
`
`strategies for this purpose.
`
`For example, Illum and others found that biodegradable microspheres
`
`based on materials such as starch could delay clearance to a period of
`
`hours as compared to a normal half life of clearance of about 10 to 15
`
`minutes (Illum et al, Int. J. Pharm., 39 (1986) 189-199). Surprisingly,
`
`such systems were also found to give an improved absorption by affecting
`
`the integrity of the tight junctions of the epithelial cells in the nasal cavity
`
`and are expected therefore to be best suited to drugs acting systemically.
`
`Similarly,
`
`Illum and others have shown that
`
`the bioadhesive material
`
`chitosan can modify mucociliary clearance with an increase in drug
`
`absorption (Illum ez al, Pharm Res. , 11 (1994) 1186-1189).
`
`It would be most beneficial, due to ease of use and of administration, to
`
`have available a simple solution spray system that was suitable for the
`
`administration of drugs to the nose and, better still,
`
`for
`
`the drugs
`
`administered via such a system to have a long retention in the nasal cavity.
`
`The skilled person may envisage various strategies to this end, including
`
`the use of pharmacological agents that decrease mucociliary clearance by a
`
`10
`
`15
`
`20
`
`25
`
`
`
`

`
`
`
`'WO 98/47535
`
`PCT/GB98/01 147
`
`3
`
`direct effect on the action of cilia, such as cocaine, as well as formulation
`
`methods such as environmentally-responsive gels.
`
`Liquids that gel
`
`in response to a change in environment are known to
`
`those skilled in the art. The environmental change can be temperature,
`
`pH or ionic strength or a combination of these factors. Examples of all of
`
`these systems can be found in the prior art literature (see, for example, the
`
`smart hydrogel from Gelmed as described by Potts er al in Proceed.
`
`Intern. Symp. Control Rel., 24, 335 (1997)). However,
`
`the majority of
`
`these have been found to be unsuitable for nasal use in man because of
`
`factors such as irritation, discomfort (eg. administration of cold solutions),
`
`mucosal damage, an unwanted enhancement of drug absorption into the
`
`systemic circulation, and many are unavailable due to lack of regulatory
`
`approval .
`
`In summary, it would present considerable advantages to provide a single
`
`component nasal delivery system, which was in the form of a liquid for
`
`ease of administration, and in particular one that gelled in the nose upon
`
`contact with the nasal tissues, which could be used to administer, and to
`
`modify absorption characteristics, of drugs (therapeutic agents) intended to
`
`act locally or systemically.
`
`It would also be desirable to provide a system
`
`which is well accepted by patients, does not enhance the absorption of
`
`drug intended for a local effect into the systemic circulation (as this could
`
`lead to side effects), and comprises materials that are approved by
`
`10
`
`15
`
`20
`
`25
`
`regulatory authorities.
`
`Those skilled in the art will appreciate that there are similar problems to
`
`be solved in respect of drug delivery for the improved treatment of
`
`conditions that affect the vaginal cavity, the rectum, the eye, and the back
`
`
`
`

`
`
`
`WO 98/47535
`
`PCT/GB98/01147
`
`4
`
`of the throat, as well as for the improved delivery of vaccines to the local
`
`lymphoid tissue, or for the improved delivery of DNA for the transfection
`
`of epithelial cells.
`
`For example, drugs intended for the treatment of vaginal infections, or
`
`drug free formulations intended to act as vaginal moisturising agents
`
`(especially useful in post—menopausal conditions), should spread well
`
`in
`
`the vaginal cavity and be retained for long periods of time. However, it
`
`has been reported that so—called bioadhesive formulations that are intended
`
`10
`
`to be retained in the vaginal cavity for days can be expelled rapidly, with
`
`more that 80% of the dose leaving the vagina in less than 2 hours (Brown
`
`et al, 14, 1073 (1997)). Thus,
`
`it would be advantageous to provide a
`
`single component liquid composition that could be inserted into the vagina
`
`as a simple liquid and that gelled under the local environmental conditions
`
`15
`
`to give good retention.
`
`For rectal enemas, it would be most beneficial if the liquid enema formed
`
`a gel once applied, ensuring close contact with the local environment and
`
`preventing early discharge.
`
`20
`
`25
`
`Similar problems may be identified in respect of administration to the eye,
`
`by virtue of the fact that liquid formulations are rapidly cleared from the
`
`eye through drainage down the naso-lacrymal duct. A single component
`
`liquid composition that gelled upon application to the eye would be
`
`advantageous for the treatment of conditions such as eye infections and
`
`inflammation.
`
`Pectins are materials which are found in the primary cell wall of all green
`
`land plants. They are heterogeneous materials, with a polysaccharide
`
`
`
`

`
`
`
`' WO 98/47535
`
`PCT/GB98/01147
`
`5
`
`backbone that is uniform as ot-1,4-linked polygalacturonic acid. Various
`
`neutral sugars have been identified in pectins such as xylose, galactose,
`
`rhamnose, arabinose.
`
`A critical property of pectins, which is known to affect their gelation
`
`properties, is the extent to which the galacturonic acid units are esterified.
`
`The degree of esterification (DE) of pectins found naturally can vary
`
`considerably (from 60_ to 90%). The term DE is well understood by those
`
`skilled in the art and may be represented as the percentage of the total
`
`10
`
`number of carboxyl groups which are esterified, or as the methoxyl
`
`content of the pectin. The respective theoretical maximum for each is
`
`100% and 16% respectively. DE as used herein refers to the total number
`
`of carboxyl groups which are esterified.
`
`Low DE pectins (ie.
`
`those
`
`having less than 50% esterification) are usually prepared by the de-
`
`esterification of extracted pectins, normally on a bench scale, by way of
`
`an enzymatic process, or, on an industrial scale, by the treatment with
`
`acid or ammonia in an alcoholic heterogeneous medium. For pectins with
`
`a low degree of methoxylation (DM;
`
`less
`
`than 45%)
`
`the gelation
`
`properties are known to depend on the DM and the molecular weight of
`
`the pectin. The chemistry of low methoxyl pectin gelation is described by
`
`Axelos and Thibault
`
`in “The Chemistry and Technology of Pectin”,
`
`Academic Press, New York, pp. 109-118, (1991).
`
`Various prior art documents discuss the potential use of pectin as a
`
`bioadhesive and gelling material.
`
`Studies by Smart er al, J. Pharm.
`
`Pharmacol. 36, 295 (1984)
`
`in relation to the adhesiveness of various
`
`materials to mucus have shown that pectin is poorly adhesive in in vitro
`
`tests. A tablet capable of adhering to the mucus membrane containing
`
`pectin has been described in EP 306 454. Oechslein et al (Int. J. Phar1n.,
`
`20
`
`25
`
`
`
`

`
`
`
`"W0 98/47535
`
`.
`
`6
`
`PCT/GB98/01147
`
`139,
`
`(1994), 25-32), have described the potential of various powder
`
`formulations to enhance the nasal absorption of the somatostatin analogue
`
`peptide octreotide. Pectin (type FPA) powder was used, and gave rise to
`
`an increase in the absolute bioavailability of the drug as compared to the
`
`drug administered in a saline solution.
`
`In none of these documents was
`
`the use of a solution formulation containing a pectin with a low DE, or a
`
`pectin that gels in contact with nasal secretions, described.
`
`Pectin has also been studied as a mucoadhesive ophthalmic material by
`
`10
`
`Chetoni et al (Bull. Chem. Farm., 135, 147 (1996)). Salt complexes of
`
`drugs with pectin for administration to the oral mucosa as patches have
`
`been described by Burgalassi et al, World Meet. Pharm. Biopharrn.
`
`Pharrn. Technol., (1995), p. 839, APGI, Paris. Popovici and Szasz (in
`
`“Buccal
`
`and Nasal Administration
`
`as Alternatives
`
`to Parenteral
`
`Administration”, Minutes of a European Symposium (1992), Duchene,
`
`D., Ed., Sante, Paris, France. p. 292-6) have described mucoadhesive
`
`hydrogels containing cellulose and pectin and a bivalent cation in the form
`
`of magnesium. The use of a low DE pectin as a solution that would gel in
`
`contact with mucosal
`
`surfaces was not described in any of
`
`these
`
`20
`
`documents .
`
`US 4,826,683 describes a nasal decongestant containing vegetable oil, aloe
`
`Vera, zinc, vitamin C, vitamin A, vitamin E, Vitamin B6, biotin and fruit
`
`pectin. The content of fruit pectin was to a maximum of 2 g per litre.
`
`25
`
`The solubilised fruit pectin supplied by General Foods under the trade
`
`name “Certo” was preferred.
`
`JP 62236862 describes an artificial mucus
`
`composed of a mixture of a spinnable water soluble polymer and a
`
`polysaccharide, protein or vinyl polymer.
`
`Pectin is listed as a suitable
`
`polysaccharide, though the type of pectin is not specified.
`
`
`
`

`
`
`
`"W0 98/47535
`
`PCT/GB98/01147
`
`US 5,147,648 (EP 289 512) describes a pharmaceutical formulation made
`
`from at least two components which, when added separately, can form a
`
`gel for treating a mucosa. The two components are applied separately to
`
`the same area of a mucous membrane. The components may be added
`
`simultaneously or
`
`sequentially.
`
`One of
`
`the gel
`
`forming solution
`
`components includes a calcium salt (eg. calcium gluconate) and the other
`
`may include a pectin. There is no suggestion in this prior art document
`
`that a solution comprising pectin may be administered as a single
`
`10
`
`component,
`
`in the absence of a separately applied solution of calcium
`
`ions, which will gel once in contact with the mucosa.
`
`US 5,318,780 describes aqueous pharmaceutical vehicles containing two
`
`components,
`
`a
`
`film forming polymer
`
`(eg.
`
`pectin)
`
`and
`
`an ionic
`
`polysaccharide, which are then gelled in situ by contacting the mixture
`
`with a counter-ion. Polygalacturomc acids such as pectin are mentioned in
`
`an extensive listing of representative useful polymers for application in the
`
`eye as corneal mastis protective corneal shields. No examples of the use
`
`of a pectin solution alone, nor of pectins with a low DE, or pectins that
`
`would gel in contact with the mucosa, are disclosed.
`
`The preparation of pectin beads by ionotropic gelation has been described
`
`by Aydin and Akburfa (1996) Int. J. Pharrn., 137, 133-136.
`
`In summary, although it is known in the art that all pectins will form gels
`
`in the presence of calcium ions, for the pectins employed previously in
`
`pharmaceutical systems to be applied to mucosal surfaces,
`
`it has been
`
`hitherto understood that high levels of calcium are needed, which levels
`
`are well above physiological concentrations.
`
`This has necessitated the
`
`20
`
`25
`
`
`
`

`
`
`
`WO 98/47535
`
`,
`
`8
`
`PCT/GB98/0l147
`
`utilisation of pectin systems which are applied either in the form of
`
`preformed gels, or before or after the addition of exogenous calcium in
`
`order to produce a gel
`
`in situ.
`
`That
`
`liquids (especially solutions)
`
`comprising low DE pectins may be applied as such, and may gel upon, or
`
`just after, application to mucosa is neither described nor suggested in any
`
`of the aforementioned prior art documents. Further, the importance of the
`
`DB of pectin upon such gelation properties is not mentioned in any of
`
`these prior art documents.
`
`We have now found, surprisingly,
`
`that certain pectin materials, namely
`
`those with a low DE, may be administered in the form of single
`
`component, simple liquid formulations (ie. in an aqueous carrier) which
`
`will gel, or can be readily adapted to gel, upon application to mucosa in
`
`the nasal, rectal and vaginal cavities,
`
`in the eye, or at the back of the
`
`throat. We have also found, surprisingly,
`
`that gelation may occur at
`
`physiologically acceptable pH values in the presence of very much
`
`reduced
`
`calcium concentrations,
`
`ie.
`
`those which
`
`can
`
`be
`
`found
`
`physiologically in the nasal secretions, as well as in the vaginal lumen, the
`
`rectal cavity and the tear fluid of the eye.
`
`5
`
`10
`
`20
`
`According to a first aspect of the invention there is provided a single
`
`component
`
`liquid pharmaceutical composition for administration to a
`
`mucosal surface comprising a therapeutic agent, a pectin with a low DE
`
`and an aqueous carrier, that gels or can be adapted to gel at the site of
`
`25
`
`application.
`
`We have found,
`
`in particular,
`
`that such compositions gel, or can be
`
`adapted to gel, at the site of, and upon, or just after, application to a
`
`mucosal surface in the absence of an extraneously (ie. separately and/or
`
`
`
`

`
`
`
`WO 98/47535
`
`PCT/GB98/01147
`
`9
`
`independently) applied (simultaneously or sequentially) solution of calcium
`
`(or other divalent metal) ions. There is thus provided a single component
`
`liquid pharmaceutical composition for application directly to a mucosal
`
`surface comprising a therapeutic agent, a pectin with a low DE and an
`
`aqueous carrier, which composition is adapted to gel at
`
`the site of
`
`application in the absence of an extraneous source (eg.
`
`solution) of
`
`divalent metal ions applied to the same site.
`
`According to a further aspect of the invention, there is provided a kit of
`
`parts comprising a liquid pharmaceutical composition for administration to
`
`a mucosal surface, comprising a therapeutic agent, a pectin with a low DE
`
`and an aqueous carrier, provided that the kit does not comprise a solution
`
`of divalent metal ions to be added extraneously to said surface.
`
`In particular,
`
`there is provided a kit of parts comprising a liquid
`
`pharmaceutical composition for administration to a mucosal surface,
`
`which composition comprises a therapeutic agent, a pectin with a low DE
`
`and an aqueous carrier, and which kit of parts is packaged and presented
`
`with instructions to administer said composition to said surface in the
`
`10
`
`15
`
`20
`
`absence of an extraneous source of divalent metal ions.
`
`The liquid pharmaceutical compositions for administration to mucosal
`
`surfaces comprising therapeutic agent, low DE pectin and aqueous carrier,
`
`which are, or are to be,‘ administered as a single component, and which
`
`25
`
`gel, or are adapted to gel,
`
`in the absence of an extraneous source of
`
`divalent metal ions are referred to hereinafter as “the compositions of the
`
`invention” .
`
`
`
`

`
`
`
`‘WO 98/47535
`
`PCTlGB98/01 147
`
`10
`
`By “liquid” composition, we mean a composition which is in the form of a
`
`mobile fluid upon application to the mucosa. The compositions of the
`
`invention are in the form of an aqueous formulation comprising a solution,
`
`a suspension, or an emulsion,
`
`including pectin and therapeutic agent,
`
`in
`
`water. The compositions of the invention will gel, or may be adapted to
`
`gel, upon, or shortly (eg. up to 5 minutes) after, application, to a form a
`
`solid or semi-solid gel material, which gel
`
`is suitable to provide a
`
`retaining effect at the site of administration.
`
`10
`
`15
`
`20
`
`25
`
`By
`
`“degree of esterification (DE)”, we mean the percentage of
`
`galacturonic acid units which are esterified, for example as described in
`
`the article by Walter in “The Chemistry and Technology of Pectin”,
`
`Academic Press, New York (1991), p. 192. By “low DE”, we mean a
`
`pectin in which less than 50%, and more preferably less than 35%, of the
`
`galacturonic acid units are esterified.
`
`By “extraneous source” of divalent metal
`
`ions, we include a separate
`
`and/or independent (ie. exogenous) source of such ions.
`
`Ions which are
`
`present in a gel resulting from administration of a composition of the
`
`invention to a mucosa are not derived from either the composition, or
`
`from the bodily secretions of the patient to which the composition is to be
`
`applied (eg. endogenous ions derived from nasal secretions,
`
`tear fluid,
`
`etc.). Divalent metal ions which may be mentioned include calcium ions.
`
`According to a further aspect of the invention,
`
`there is provided a
`
`pharmaceutical
`
`gel
`
`composition
`
`obtainable
`
`by
`
`applying
`
`a
`
`liquid
`
`composition, comprising a therapeutic agent, a pectin with a low DE and
`
`an aqueous carrier,
`
`to a mucosal surface of a mammalian patient in the
`
`
`
`

`
`
`
`WO 98/47535
`
`PCT/GB98/01147
`
`11
`
`absence of extraneous application of a solution of divalent metal ions to
`
`said surface.
`
`The gels so formed upon contact with mucosal surfaces will contain only
`
`endogenous divalent metal ions (i.e.
`
`those derived directly from bodily
`
`secretions) and will not include exogenous divalent metal ions (i.e those
`
`derived from an extraneous source). According to a further aspect of the
`
`invention there is provided a pharmaceutical gel composition, which gel
`
`comprises a therapeutic agent and a pectin with a low DE, which gel is
`
`10
`
`obtainable by applying a liquid composition, comprising said therapeutic
`
`agent and pectin in an aqueous carrier, to a mucosal surface, and which
`
`gel is substantially free of divalent metal ions derived from an extraneous
`
`source applied to said mucosal surface before, or at the same time as, or
`
`after, said liquid composition is applied.
`
`20
`
`25
`
`Because the compositions of the invention are not added in conjunction
`
`with an extraneous source of such ions, by “substantially free” of divalent
`
`metal ions, we mean greater than 97%, preferably greater than 99%, more
`
`preferably greater than 99.9%, and especially greater than 99.99% free.
`
`Pectins with a low DE can be obtained from known sources, or can be
`
`obtained via de-esterification of high DE pectins (which may be obtained
`
`from, for example, Sigma Fine Chemicals),
`
`in accordance with known
`
`techniques, such as those described in the article by Rollin in “Industrial
`
`Gums”, Academic Press, New York (1993) p. 257, or as described
`
`hereinbefore.
`
`Low DE pectin may,
`
`for example, be obtained from
`
`Copenhagen Pectin A/S as the commercial material known as Slendid
`
`Type 100 and Slendid Type 110. These pectins have been extracted from
`
`citrus peel
`
`and
`
`standardised by
`
`the
`
`addition of
`
`sucrose.
`
`The
`
`
`
`

`
`WO 98/47535
`
`PCT/GB98/01147
`
`12
`
`standardisation process is as described by Rollin in the abovementioned
`
`article. The DE is less than 50% for both pectins and of the order of 10%
`
`for type 100 and 35% for type 110. Further materials which may be
`
`employed include GENU pectin types LM 1912 CS and Pomosin pectin
`
`types LM 12 CG and LM 18 CG.
`
`The compositions of the invention may be prepared by dissolving or
`
`dispersing the pectin of low DE and therapeutic agent
`
`in an aqueous
`
`system,
`
`to form a solution, a suspension or an emulsion in accordance
`
`10
`
`with known techniques.
`
`For example,
`
`the therapeutic agent may be
`
`dissolved in a prior prepared aqueous solution of the pectin, or may be
`
`added as, or to form, a suspension in an aqueous system, where the drug
`
`particles are less than 100 microns in size, preferably between 1 and 20
`
`microns. Alternatively, drug may be dissolved or suspended in a suitable
`
`oily vehicle such as a vegetable oil, and then dispersed into the aqueous
`
`pectin solution to form an emulsion.
`
`It will be appreciated by those
`
`skilled in the art that the type of aqueous formulation so developed will
`
`depend upon to mucosa to be treated, as well as the dose, and the physical
`
`characteristics and properties, of the drug (e.g.
`
`its solubility, basicity
`
`20
`
`etc.).
`
`The concentration of low DE pectin in compositions of the invention
`
`depends upon the nature of the pectin, the presence of other components,
`
`and other factors which influence gelation properties of the composition
`
`25
`
`(see below), but may be from 1 g/L to 100 g/L, and is preferably from 1
`
`g/L to 50 g/L, more preferably from 2 g/L to 10 g/L and especially from
`
`5 g/L to 10 g/L.
`
`
`
`

`
`WO 98/47535
`
`PCT/GB98/01147
`
`13
`
`Compositions of the invention may be used with a View to the prevention
`
`of a major problem in the delivery of drugs to the nose for local treatment,
`
`namely the rapid mucociliary clearance mechanism. This natural process,
`
`which removes deposited material from the front of the nose to the throat,
`
`can clear material from the nose with a half—time of about 10 to 20
`
`minutes. Such clearance rates can be measured readily in man using the
`
`saccharin clearance test or by gamma scintigraphy (Aspden et al, J.
`
`Pharm. Sci., 86, 509 (1997); Illum et al, Int.
`
`J. Pharm., 39 (1987) 189-
`
`199).
`
`10
`
`15
`
`20
`
`25
`
`Compositions of the invention may be employed to retain a therapeutic
`
`agent which is intended to act locally at a mucosal surface for a relatively
`
`long period when compared to mucosal delivery systems known in the art.
`
`If the therapeutic agent is easily absorbed, absorption may be retarded,
`
`thus keeping more of the drug at
`
`the site of application, where it
`
`is
`
`needed.
`
`Therapeutic agents which may be employed in the compositions of the
`
`invention include,
`
`for nasal administration, drugs that are employed
`
`locally to treat conditions such as rhinitis, viral infections, as well as those
`
`which act as decongestants. The compositions of the invention may also
`
`be used as a way of improving the delivery of vaccines to the nose
`
`associated lymphoid tissue and for the better presentation of DNA for the
`
`transfection of nasal epithelial cells.
`
`The following list of therapeutic agents are suitable for use in the
`
`compositions of the invention, for local treatment of a mucosal surface, is
`
`provided by way of illustration and is not meant to be exclusive: antiviral
`
`agents such as [CAM-l, pirovadir, acyclovir, bromovinyldeoxyuridine, ot,
`
`
`
`

`
`
`
`WO 98/47535
`
`PCT/GB98/01147
`
`14
`
`B and 7-interferon, zidovudine; decongestants such as oxymetazaline; anti-
`
`allergic agents, such as sodium cromoglycate and budesonide; steroids,
`
`such as fluticazone; vaccines, such as DNA, influenza, pertussis, measles
`
`and diphtheria vaccines; antibacterial agents; antifungal agents, such as
`
`amphotericin, nystatin; contraceptive and/or spermicidal agents; antibodies
`
`especially for the treatment of RSV infection in children; prophylactic
`
`agents
`
`against HIV;
`
`antihistamines,
`
`such
`
`as
`
`diphenhydramine
`
`hydrochloride; genes.
`
`10
`
`Combinations of the abovementioned therapeutic agents may also be
`
`employed.
`
`Compositions of the invention may also be employed to control the plasma
`
`level versus time profile for readily absorbable drugs which are intended
`
`to act systemically (ie. to give a flatter profile), either by altering the rate
`
`of transport into the general circulation, or by retarding absorption of
`
`readily absorbable drugs. This can, for example, be of importance when
`
`side effects from high peak plasma levels are to be avoided.
`
`20
`
`25
`
`The compositions of the invention may thus be used for the modification
`
`of the systemic absorption of mucosally administered drugs, including, but
`
`not limited to, apomorphine, nicotine, hyoscine hydrobromide, lignocaine,
`
`fentanyl, naratriptan, pheromones and propranolol.
`
`Combinations of the abovementioned therapeutic agents may also be
`
`employed.
`
`
`
`

`
`
`
`WO 98/47535
`
`a
`
`15
`
`PCT/GB98/01 147
`
`For the avoidance of doubt,
`
`the term “therapeutic agents” is intended
`
`herein to include agents which are suitable for use in the treatment, and in
`
`the prevention, of disease.
`
`The compositions of
`
`the
`
`invention may be used to treat/prevent
`
`diseases/conditions in mammalian patients depending upon the therapeutic
`
`agent(s) which is/are employed. For the above, non—exhaustive lists of
`
`locally acting and systemic drugs, diseases/conditions which may be
`
`mentioned include those against which the therapeutic agent(s) in question
`
`10
`
`are known to be effective, and include those specifically listed for the
`
`drugs in question i11 Martindale,
`
`“The Extra Pharmacopoeia”, 31st
`
`Edition, Royal Pharmaceutical Society (1996).
`
`Preferred drugs include nicotine and apomorphine.
`
`The amount of
`
`therapeutic agent which may be employed in the
`
`compositions of the invention will depend upon the agent which is used, and
`
`the disease to be treated, but may be in the range 0.01 to 40% w/w.
`
`However,
`
`it will be clear to the skilled person that suitable doses of
`
`therapeutic agents can be readily determined non-inventively. For example,
`
`estimates of dosage can be made from known injectable products assuming
`
`that from 0.1 to 90% of the dose is absorbed. Suitable single unit doses are
`
`in the range 10 ug to 500 mg depending upon the therapeutic agent(s) which
`
`is/are employed and the route of administration. Suitable daily doses are in
`
`the range 10 ug to l g/day depending upon the therapeutic agent(s) which
`
`20
`
`25
`
`is/are employed and the route of administration.
`
`Most compositions comprising drug and a low DE pectin will gel upon
`
`application at the site of application,
`
`i.e. upon, or shortly (e.g. up to 5
`
`
`
`

`
`
`
`WO 98/47535
`
`PCT/GB98/01147
`
`.
`
`16
`
`minutes) after, contact with the relevant mucosal surface. However,
`
`in
`
`some formulations, the nature of the drug and/or the pectin which is/are
`
`employed may require that the composition is adapted such that it gels
`
`upon, or shortly (e.g. up to 1 minute) after, contact. This may be achieved
`
`readily via techniques which are well known to those skilled in the art:
`
`For example,
`
`the concentration of pectin may be selected such that the
`
`aqueous formulation will gel once in contact with the mucosal surface.
`
`10
`
`Furthermore,
`
`the addition of monovalent ions to aid the gelling process
`
`may be required (for example, simple monovalent electrolytes, eg. NaC1,
`
`may be added to adapt the liquid formulation to gel, as well as to provide
`
`isotonicity) .
`
`The quantity and nature of the drug in the aqueous formulation may also
`
`have an influence on the gelation properties. For example, the addition of
`
`a high level of a certain drugs, including those which are weak bases (such
`
`as nicotine), which are known to form reversible complexes with anionic
`
`materials such as pectin, may require a change in the ratio between drug
`
`and pectin, so that preferably 30%, more preferably 50%, and most
`
`preferably 60%, of the negative charges on the pectin molecule are
`
`uncomplexed.
`
`Alternatively, sugars in the form of, for example, sucrose can be added to
`
`the formulation to aid gelation. Non-ionic polysaccharides (such as
`
`hydroxypropyl methyl cellulose) may also be used.
`
`The pH of the composition has also been found to affect gelation
`
`properties. The pH of the compositions of the invention may be from 2 to
`
`20
`
`25
`
`
`
`

`
`
`
`WO 98/47535
`
`9
`
`17
`
`PCT/GB98/01147
`
`9, more preferably from 3 to 8 and most preferably from 4 to 7, taking
`
`into account the gelation properties of the composition and the properties
`
`of the therapeutic agent. For example, in general, we have found that the
`
`lower the DB of the pectin,
`
`the lower the pH at which the composition
`
`will gel. pH may be adjusted in accordance with techniques which will be
`
`well known to those skilled in the art,
`
`such as
`
`the addition of
`
`pharmaceutically acceptable buffering agents, especially those of low ionic
`
`strength. Axelos and Thibault
`
`in_ “The Chemistry and Technology of
`
`Pectin”, Academic Press, New York, pp. 109-118, (1991) describe how
`
`the gelation properties of low DE pectin solutions are somewhat sensitive
`
`to pH and ionic strength.
`
`The abovementioned techniques, which may be used to adapt
`
`the
`
`compositions of the invention to gel, may be investigated and determined
`
`in the normal course of routine experimentation by those skilled in the art.
`
`Combinations of these techniques may also be employed in order to affect
`
`gelation properties.
`
`The compositions may also contain other additives
`
`in the form of
`
`pharmaceutical excipients, such as preservatives (e.g.
`
`low concentrations
`
`of materials such as sodium metabisulphate), stabili

This document is available on Docket Alarm but you must sign up to view it.


Or .

Accessing this document will incur an additional charge of $.

After purchase, you can access this document again without charge.

Accept $ Charge
throbber

Still Working On It

This document is taking longer than usual to download. This can happen if we need to contact the court directly to obtain the document and their servers are running slowly.

Give it another minute or two to complete, and then try the refresh button.

throbber

A few More Minutes ... Still Working

It can take up to 5 minutes for us to download a document if the court servers are running slowly.

Thank you for your continued patience.

This document could not be displayed.

We could not find this document within its docket. Please go back to the docket page and check the link. If that does not work, go back to the docket and refresh it to pull the newest information.

Your account does not support viewing this document.

You need a Paid Account to view this document. Click here to change your account type.

Your account does not support viewing this document.

Set your membership status to view this document.

With a Docket Alarm membership, you'll get a whole lot more, including:

  • Up-to-date information for this case.
  • Email alerts whenever there is an update.
  • Full text search for other cases.
  • Get email alerts whenever a new case matches your search.

Become a Member

One Moment Please

The filing “” is large (MB) and is being downloaded.

Please refresh this page in a few minutes to see if the filing has been downloaded. The filing will also be emailed to you when the download completes.

Your document is on its way!

If you do not receive the document in five minutes, contact support at support@docketalarm.com.

Sealed Document

We are unable to display this document, it may be under a court ordered seal.

If you have proper credentials to access the file, you may proceed directly to the court's system using your government issued username and password.


Access Government Site

We are redirecting you
to a mobile optimized page.





Document Unreadable or Corrupt

Refresh this Document
Go to the Docket

We are unable to display this document.

Refresh this Document
Go to the Docket